|
US7235537B2
(en)
*
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
KR100984595B1
(ko)
|
2002-03-13 |
2010-09-30 |
어레이 바이오파마 인크. |
Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
|
|
AU2003297925A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Smithkline Beecham Corporation |
Thrombopoietin mimetics
|
|
DE602004020741D1
(de)
*
|
2003-02-26 |
2009-06-04 |
Kowa Co |
Mittel zur behandlung der allergischen kontaktdermatitis
|
|
ES2331246T3
(es)
|
2003-07-24 |
2009-12-28 |
Warner-Lambert Company Llc |
Derivados de benzamidazol como inhibidores del mek.
|
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
WO2005028447A1
(en)
|
2003-09-22 |
2005-03-31 |
S*Bio Pte Ltd |
Benzimidazole derivates: preparation and pharmaceutical applications
|
|
CN1905873A
(zh)
*
|
2003-11-19 |
2007-01-31 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
|
US7517994B2
(en)
*
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
US7732616B2
(en)
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
NZ590160A
(en)
|
2003-11-21 |
2012-07-27 |
Array Biopharma Inc |
AKT protein kinase inhibitors
|
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
|
ZA200703912B
(en)
|
2004-10-20 |
2008-09-25 |
Serono Lab |
3-arylamino pyridine derivatives
|
|
EP1828184B1
(en)
*
|
2004-12-01 |
2009-09-16 |
Merck Serono SA |
[1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
|
|
US7429667B2
(en)
*
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
|
ES2405785T3
(es)
*
|
2005-05-18 |
2013-06-03 |
Array Biopharma Inc. |
Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
|
|
AU2006262375A1
(en)
*
|
2005-06-23 |
2007-01-04 |
Array Biopharma Inc. |
SNAr process for preparing benzimidazole compounds
|
|
CA2612419C
(en)
*
|
2005-06-23 |
2017-06-13 |
Array Biopharma Inc. |
Process for preparing benzimidazole compounds
|
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
SI1934174T1
(sl)
*
|
2005-10-07 |
2011-08-31 |
Exelixis Inc |
Inhibitorji MEK in postopki za njihovo uporabo
|
|
AU2012261703B2
(en)
*
|
2005-10-07 |
2015-08-13 |
Exelixis, Inc. |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
AU2013203939B2
(en)
*
|
2005-10-07 |
2015-08-13 |
Exelixis, Inc. |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
US7968108B2
(en)
*
|
2005-10-25 |
2011-06-28 |
Metbro Distributing L.P. |
Hydrogen cyanamide pesticide formulations
|
|
US7572460B2
(en)
*
|
2005-10-25 |
2009-08-11 |
Rodrigo Rodriguez-Kabana |
Hydrogen cyanamide pesticide formulations
|
|
TWI405756B
(zh)
|
2005-12-21 |
2013-08-21 |
Array Biopharma Inc |
新穎硫酸氫鹽
|
|
WO2007071951A1
(en)
*
|
2005-12-21 |
2007-06-28 |
Astrazeneca Ab |
Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
|
|
RU2418790C3
(ru)
*
|
2005-12-21 |
2022-03-14 |
Астразенека Аб |
Новая гидросульфатная соль
|
|
CA2534243A1
(fr)
|
2006-01-25 |
2007-07-25 |
Hydro Quebec |
Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
|
JP5269762B2
(ja)
*
|
2006-04-18 |
2013-08-21 |
アーディア・バイオサイエンシーズ・インコーポレイテッド |
Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
|
|
CA2656566C
(en)
|
2006-07-06 |
2014-06-17 |
Array Biopharma Inc. |
Dihydrofuro pyrimidines as akt protein kinase inhibitors
|
|
ATE523499T1
(de)
|
2006-07-06 |
2011-09-15 |
Array Biopharma Inc |
Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
|
|
ATE532789T1
(de)
|
2006-07-06 |
2011-11-15 |
Array Biopharma Inc |
Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
|
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
US8492378B2
(en)
|
2006-08-03 |
2013-07-23 |
Takeda Pharmaceutical Company Limited |
GSK-3β inhibitor
|
|
ZA200901009B
(en)
*
|
2006-08-21 |
2010-05-26 |
Genentech Inc |
Aza-benzothiophenyl compounds and methods of use
|
|
ES2528797T3
(es)
*
|
2006-08-21 |
2015-02-12 |
Genentech, Inc. |
Compuestos de aza-benzotiofenilo y métodos de uso
|
|
AU2007286808B2
(en)
*
|
2006-08-21 |
2012-12-06 |
Genentech, Inc. |
Aza-benzofuranyl compounds and methods of use
|
|
PL2101759T3
(pl)
|
2006-12-14 |
2019-05-31 |
Exelixis Inc |
Sposoby stosowania inhibitorów MEK
|
|
JO2985B1
(ar)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
|
US20100130519A1
(en)
*
|
2007-04-13 |
2010-05-27 |
Stephen Robert Wedge |
Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
|
|
US8509487B2
(en)
*
|
2007-04-19 |
2013-08-13 |
Avago Technologies General Ip (Singapore) Pte. Ltd. |
System and method for optically measuring a parameter of an object
|
|
JP5580735B2
(ja)
|
2007-06-12 |
2014-08-27 |
ジェネンテック， インコーポレイテッド |
Ｎ−置換アザインドール類及び使用方法
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
CN101918373B
(zh)
|
2007-07-05 |
2013-06-05 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
WO2009006567A2
(en)
|
2007-07-05 |
2009-01-08 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
MX2010004074A
(es)
*
|
2007-10-15 |
2010-07-02 |
Astrazeneca Ab |
Combinacion 059.
|
|
ES2456966T3
(es)
|
2007-11-12 |
2014-04-24 |
Takeda Pharmaceutical Company Limited |
Inhibidores de MAPK/ERK cinasa
|
|
JP5421925B2
(ja)
|
2007-12-19 |
2014-02-19 |
ジェネンテック， インコーポレイテッド |
５−アニリノイミダゾピリジン及び使用の方法
|
|
US8293763B2
(en)
|
2007-12-19 |
2012-10-23 |
Genentech, Inc. |
8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
|
|
JP2011506533A
(ja)
|
2007-12-20 |
2011-03-03 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｍｅｋキナーゼ阻害剤としての置換ヒダントイン
|
|
CA2708176A1
(en)
|
2007-12-21 |
2009-07-02 |
Genentech, Inc. |
Azaindolizines and methods of use
|
|
ES2422733T3
(es)
|
2008-01-09 |
2013-09-13 |
Array Biopharma Inc |
Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
|
|
EP2240455B1
(en)
*
|
2008-01-09 |
2012-12-26 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
|
|
EP2240494B1
(en)
|
2008-01-21 |
2016-03-30 |
UCB Biopharma SPRL |
Thieno-pyridine derivatives as mek inhibitors
|
|
SA109300195B1
(ar)
|
2008-03-28 |
2013-04-20 |
Astrazeneca Ab |
تركيبة صيدلانية جديدة مضادة للسرطان
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
EP2293472A1
(en)
|
2008-06-23 |
2011-03-09 |
Panasonic Corporation |
Wireless communication base station apparatus and reference signal allocation method
|
|
ES2426096T3
(es)
*
|
2008-07-01 |
2013-10-21 |
Genentech, Inc. |
Derivados de isoindolona como inhibidores de la quinasa MEK y métodos de utilización
|
|
US8841462B2
(en)
|
2008-07-01 |
2014-09-23 |
Robert A. Heald |
Bicyclic heterocycles as MEK kinase inhibitors
|
|
HRP20160044T1
(hr)
|
2008-08-04 |
2016-02-26 |
Merck Patent Gmbh |
Novi spojevi fenilamino izonikotinamida
|
|
CN101653607B
(zh)
*
|
2008-08-19 |
2013-02-13 |
鼎泓国际投资（香港）有限公司 |
含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
|
|
WO2010051245A1
(en)
*
|
2008-11-03 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Benzimidazole and aza-benzimidazole carboxamides
|
|
US8993630B2
(en)
|
2008-11-10 |
2015-03-31 |
Bayer Intellectual Property Gmbh |
Substituted sulphonamido phenoxybenzamides
|
|
AR077975A1
(es)
|
2009-08-28 |
2011-10-05 |
Irm Llc |
Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
EP2491014A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted halophenoxybenzamide derivatives
|
|
US20120269803A1
(en)
|
2009-10-21 |
2012-10-25 |
Bayer Intellectual Property Gmbh |
Substituted benzosulphonamides
|
|
EP2491015A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
|
WO2011131748A2
(en)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Novel inhibitors
|
|
JP2013529619A
(ja)
|
2010-06-25 |
2013-07-22 |
ノバルティス アーゲー |
タンパク質キナーゼ阻害剤としてのヘテロアリール化合物および組成物
|
|
CA2807510A1
(en)
|
2010-08-05 |
2012-02-09 |
Case Western Reserve University |
Inhibitors of erk for developmental disorders of neuronal connectivity
|
|
MY170236A
(en)
|
2010-10-06 |
2019-07-11 |
Glaxosmithkline Llc |
Benzimidazole derivatives as pi3 kinase inhibitors
|
|
WO2012055953A1
(en)
|
2010-10-29 |
2012-05-03 |
Bayer Pharma Aktiengesellschaft |
Substituted phenoxypyridines
|
|
CN102020651B
(zh)
|
2010-11-02 |
2012-07-18 |
北京赛林泰医药技术有限公司 |
6-芳基氨基吡啶酮甲酰胺mek抑制剂
|
|
EP2655601A4
(en)
|
2010-12-22 |
2014-09-10 |
Fate Therapeutics Inc |
CELL CULTURAL PLATFORM FOR INDIVIDUAL CELL SIZING AND IMPROVED RESOLUTION OF IPSCS
|
|
DK2655375T3
(en)
|
2010-12-23 |
2015-03-09 |
Sanofi Sa |
PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
|
|
RU2013148817A
(ru)
|
2011-04-01 |
2015-05-10 |
Дженентек, Инк. |
Комбинации соединений-ингибиторов акт и мек и способы их применения
|
|
WO2012135781A1
(en)
|
2011-04-01 |
2012-10-04 |
Genentech, Inc. |
Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
WO2012145503A1
(en)
|
2011-04-21 |
2012-10-26 |
Novartis Ag |
Pharmaceutical combinations
|
|
WO2012162293A1
(en)
*
|
2011-05-23 |
2012-11-29 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mek inhibitors
|
|
EP2714037B1
(en)
|
2011-05-25 |
2016-07-13 |
Université Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
|
EP3812387A1
(en)
|
2011-07-21 |
2021-04-28 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Heterocyclic protein kinase inhibitors
|
|
MX368257B
(es)
*
|
2011-08-01 |
2019-09-26 |
Genentech Inc |
Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
|
|
US10314594B2
(en)
|
2012-12-14 |
2019-06-11 |
Corquest Medical, Inc. |
Assembly and method for left atrial appendage occlusion
|
|
US10813630B2
(en)
|
2011-08-09 |
2020-10-27 |
Corquest Medical, Inc. |
Closure system for atrial wall
|
|
US10307167B2
(en)
|
2012-12-14 |
2019-06-04 |
Corquest Medical, Inc. |
Assembly and method for left atrial appendage occlusion
|
|
KR20140072028A
(ko)
|
2011-08-31 |
2014-06-12 |
노파르티스 아게 |
Pi3k- 및 mek-억제제의 상승작용적 조합물
|
|
KR20140068037A
(ko)
*
|
2011-09-01 |
2014-06-05 |
노파르티스 아게 |
누난 증후군의 치료를 위한 유기 화합물의 용도
|
|
EP2570127A1
(en)
|
2011-09-16 |
2013-03-20 |
Sanofi |
Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
|
|
AU2012323890A1
(en)
|
2011-10-14 |
2014-05-29 |
Array Biopharma Inc. |
Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them
|
|
JP2014534228A
(ja)
|
2011-11-02 |
2014-12-18 |
シンタ ファーマシューティカルズ コーポレーション |
白金含有剤とｈｓｐ９０阻害剤の組合せ療法
|
|
CA2853799A1
(en)
|
2011-11-02 |
2013-05-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
|
US9402831B2
(en)
|
2011-11-14 |
2016-08-02 |
Synta Pharmaceutical Corp. |
Combination therapy of HSP90 inhibitors with BRAF inhibitors
|
|
DK2797957T3
(da)
|
2011-11-23 |
2019-09-23 |
Medimmune Llc |
Bindingsmolekyler specifikke for her3 og anvendelser deraf
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
EP2802658A2
(en)
|
2012-01-09 |
2014-11-19 |
Novartis AG |
Rnai agents to treat beta-catenin related diseases
|
|
WO2013109142A1
(en)
|
2012-01-16 |
2013-07-25 |
Stichting Het Nederlands Kanker Instituut |
Combined pdk and mapk/erk pathway inhibition in neoplasia
|
|
CN103204825B
(zh)
|
2012-01-17 |
2015-03-04 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
|
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
|
US8961970B2
(en)
|
2012-03-20 |
2015-02-24 |
Novartis Ag |
Combination therapy
|
|
US10054835B2
(en)
|
2012-04-09 |
2018-08-21 |
Switch Materials, Inc. |
Switching materials, and compositions and methods for making same
|
|
EP4600727A3
(en)
|
2012-05-29 |
2025-10-22 |
Solutia Canada Inc. |
Optical filter comprising a variable transmittance layer
|
|
JP2015527874A
(ja)
|
2012-05-31 |
2015-09-24 |
バイエル ファーマ アクチエンゲゼルシャフト |
肝細胞癌（ｈｃｃ）患者の治療の有効な応答を決定するためのバイオマーカー
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
KR20190057421A
(ko)
|
2012-08-17 |
2019-05-28 |
에프. 호프만-라 로슈 아게 |
코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
|
|
DK2903968T3
(en)
|
2012-10-02 |
2017-01-30 |
Gilead Sciences Inc |
INHIBITORS OF HISTON DEMETHYLASES
|
|
KR102204520B1
(ko)
|
2012-10-12 |
2021-01-20 |
엑셀리시스, 인코포레이티드 |
암의 치료에 사용하기 위한 화합물의 신규 제조 방법
|
|
EP2909181B1
(en)
|
2012-10-16 |
2017-08-09 |
Tolero Pharmaceuticals, Inc. |
Pkm2 modulators and methods for their use
|
|
FI3702351T3
(fi)
|
2012-10-19 |
2024-01-24 |
Array Biopharma Inc |
MEK-inhibiittorin käsittävä koostumus
|
|
US20140142689A1
(en)
|
2012-11-21 |
2014-05-22 |
Didier De Canniere |
Device and method of treating heart valve malfunction
|
|
WO2014085381A1
(en)
|
2012-11-29 |
2014-06-05 |
Novartis Ag |
Pharmaceutical combinations
|
|
US9867825B2
(en)
|
2012-12-20 |
2018-01-16 |
Novartis Ag |
Pharmaceutical combination comprising binimetinib
|
|
EP2752191A1
(en)
|
2013-01-07 |
2014-07-09 |
Sanofi |
Compositions and methods using hdm2 antagonist and mek inhibitor
|
|
CN105229144A
(zh)
|
2013-02-22 |
2016-01-06 |
细胞动力学国际有限公司 |
通过组合的遗传工程和化学工程经由正向编程产生肝细胞
|
|
PE20151667A1
(es)
|
2013-02-27 |
2015-11-27 |
Epitherapeutics Aps |
Inhibidores de histona desmetilasas
|
|
JP6465790B2
(ja)
|
2013-02-27 |
2019-02-06 |
第一三共株式会社 |
Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
|
|
MX394360B
(es)
|
2013-03-14 |
2025-03-24 |
Sumitomo Pharma Oncology Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
|
MA38522A1
(fr)
*
|
2013-03-21 |
2017-10-31 |
Novartis Ag |
Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
|
|
AR097617A1
(es)
|
2013-09-13 |
2016-04-06 |
Actelion Pharmaceuticals Ltd |
Derivados antibacterianos del 2h-indazol
|
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
|
US9629851B2
(en)
|
2013-09-20 |
2017-04-25 |
Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis |
ROCK in combination with MAPK pathway
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
US9566443B2
(en)
|
2013-11-26 |
2017-02-14 |
Corquest Medical, Inc. |
System for treating heart valve malfunction including mitral regurgitation
|
|
EA030730B1
(ru)
|
2013-12-19 |
2018-09-28 |
Идорсиа Фармасьютиклз Лтд |
Антибактериальные производные 1h-индазола и 1h-индола
|
|
AU2015206603B9
(en)
|
2014-01-14 |
2019-07-18 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
|
|
CN104788365B
(zh)
*
|
2014-01-16 |
2018-08-10 |
上海艾力斯医药科技有限公司 |
异烟酰胺衍生物、其制备方法及应用
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
AR099612A1
(es)
|
2014-03-04 |
2016-08-03 |
Actelion Pharmaceuticals Ltd |
Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
|
|
CA2941004A1
(en)
|
2014-03-04 |
2015-09-11 |
Peter Flynn |
Improved reprogramming methods and cell culture platforms
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
CA2943824A1
(en)
|
2014-03-31 |
2015-10-08 |
Gilead Sciences, Inc. |
Inhibitors of histone demethylases
|
|
US20170107486A1
(en)
|
2014-04-21 |
2017-04-20 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
|
CA2948077A1
(en)
|
2014-05-16 |
2015-11-19 |
Actelion Pharmaceuticals Ltd |
Antibacterial quinazoline-4(3h)-one derivatives
|
|
US10023879B2
(en)
|
2014-06-04 |
2018-07-17 |
Fate Therapeutics, Inc. |
Minimal volume reprogramming of mononuclear cells
|
|
EP3563870A1
(en)
|
2014-07-15 |
2019-11-06 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
SG11201701182VA
(en)
|
2014-08-27 |
2017-03-30 |
Gilead Sciences Inc |
Compounds and methods for inhibiting histone demethylases
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
|
CA2963091A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
US10842626B2
(en)
|
2014-12-09 |
2020-11-24 |
Didier De Canniere |
Intracardiac device to correct mitral regurgitation
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
UY36462A
(es)
|
2014-12-23 |
2016-07-29 |
Novartis Ag |
Compuestos de triazolopirimidina y usos de los mismos
|
|
WO2016123100A1
(en)
|
2015-01-26 |
2016-08-04 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
CN105566225A
(zh)
*
|
2015-02-16 |
2016-05-11 |
苏州晶云药物科技有限公司 |
一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
|
|
JP2016155776A
(ja)
*
|
2015-02-24 |
2016-09-01 |
学校法人兵庫医科大学 |
抗腫瘍効果増強剤および抗腫瘍剤
|
|
EA035817B1
(ru)
|
2015-03-10 |
2020-08-14 |
Адуро Байотек, Инк. |
Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
|
|
AU2016238436A1
(en)
|
2015-03-25 |
2017-08-17 |
Novartis Ag |
Formylated N-heterocyclic derivatives as FGFR4 inhibitors
|
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
HRP20211058T8
(hr)
|
2015-07-29 |
2021-11-26 |
Novartis Ag |
Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
AR105646A1
(es)
|
2015-08-11 |
2017-10-25 |
Actelion Pharmaceuticals Ltd |
Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
|
|
WO2017033113A1
(en)
|
2015-08-21 |
2017-03-02 |
Acerta Pharma B.V. |
Therapeutic combinations of a mek inhibitor and a btk inhibitor
|
|
WO2017037579A1
(en)
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
Mdm2 inhibitors and combinations thereof
|
|
AR105889A1
(es)
|
2015-09-03 |
2017-11-22 |
Actelion Pharmaceuticals Ltd |
Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
|
|
CN117737124A
(zh)
|
2015-10-16 |
2024-03-22 |
菲特治疗公司 |
用于诱导和维护基态多能性的平台
|
|
PE20181326A1
(es)
|
2015-11-03 |
2018-08-20 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y sus usos
|
|
KR20250141836A
(ko)
|
2015-11-04 |
2025-09-29 |
페이트 세러퓨틱스, 인코포레이티드 |
만능 세포의 유전자 조작
|
|
SG11201803145RA
(en)
|
2015-11-04 |
2018-05-30 |
Fate Therapeutics Inc |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
SG11201805186VA
(en)
|
2016-01-20 |
2018-07-30 |
Fate Therapeutics Inc |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
JP7653759B2
(ja)
|
2016-01-20 |
2025-03-31 |
フェイト セラピューティクス，インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
EP3424505A4
(en)
|
2016-03-04 |
2019-10-16 |
Taiho Pharmaceutical Co., Ltd. |
PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
|
|
AR108257A1
(es)
|
2016-05-02 |
2018-08-01 |
Mei Pharma Inc |
Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
|
|
FI3463345T3
(fi)
|
2016-06-03 |
2023-01-31 |
|
Farmaseuttisia yhdistelmiä
|
|
EP3472166A1
(en)
|
2016-06-20 |
2019-04-24 |
Novartis AG |
Imidazopyrimidine compounds useful for the treatment of cancer
|
|
ES2975263T3
(es)
|
2016-06-20 |
2024-07-04 |
Novartis Ag |
Formas cristalinas de un compuesto triazolopirimidínico
|
|
WO2017221092A1
(en)
|
2016-06-20 |
2017-12-28 |
Novartis Ag |
Triazolopyridine compounds and uses thereof
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
WO2018065924A1
(en)
*
|
2016-10-04 |
2018-04-12 |
Sun Pharmaceutical Industries Limited |
Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation
|
|
WO2018092064A1
(en)
|
2016-11-18 |
2018-05-24 |
Novartis Ag |
Combinations of mdm2 inhibitors and bcl-xl inhibitors
|
|
CN108084078B
(zh)
*
|
2016-11-24 |
2021-07-30 |
中山大学 |
一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法
|
|
EP3548049A4
(en)
|
2016-12-05 |
2020-07-22 |
Fate Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
|
|
EP3372624A1
(en)
|
2017-03-06 |
2018-09-12 |
Henkel AG & Co. KGaA |
One component composition based on compounds with at least two exo-vinylene cyclic carbonate units
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
EP3712133B1
(en)
*
|
2017-11-14 |
2025-12-24 |
Shenzhen TargetRx, Inc. |
Substituted benzimidazole compound and composition comprising same
|
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
|
TW201938165A
(zh)
|
2017-12-18 |
2019-10-01 |
美商輝瑞股份有限公司 |
治療癌症的方法及組合療法
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
JP6918204B2
(ja)
|
2018-03-19 |
2021-08-11 |
大鵬薬品工業株式会社 |
アルキル硫酸ナトリウムを含む医薬組成物
|
|
KR20210003780A
(ko)
|
2018-04-05 |
2021-01-12 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Axl 키나제 억제제 및 그의 용도
|
|
PE20211916A1
(es)
|
2018-05-24 |
2021-09-28 |
Janssen Biotech Inc |
Agentes aglutinantes del psma y usos de estos
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
LT4541381T
(lt)
|
2018-07-25 |
2026-03-25 |
Advanced Accelerator Applications S.A. |
Stabilūs, koncentruoti radionuklidų kompleksų tirpalai
|
|
JP2021531306A
(ja)
|
2018-07-25 |
2021-11-18 |
アドバンスド アクセラレーター アプリケーションズ エスエー |
神経内分泌腫瘍の処置の方法
|
|
AU2019310590A1
(en)
|
2018-07-26 |
2021-01-14 |
Sumitomo Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
PT3837256T
(pt)
|
2018-08-17 |
2023-05-23 |
Novartis Ag |
Compostos e composições de ureia como inibidores de smarca2/brm-atpase
|
|
WO2020064693A1
(en)
|
2018-09-25 |
2020-04-02 |
Advanced Accelerator Applications (Italy) Srl |
Combination therapy
|
|
WO2020106305A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Thienyl-aniline compounds for treatment of dermal disorders
|
|
WO2020106308A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
|
WO2020106306A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
KR20260008165A
(ko)
|
2019-02-12 |
2026-01-15 |
스미토모 파마 아메리카, 인크. |
헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EA202192575A1
(ru)
|
2019-03-21 |
2022-01-14 |
Онксео |
Соединения dbait в сочетании с ингибиторами киназ для лечения рака
|
|
KR20210141621A
(ko)
|
2019-03-22 |
2021-11-23 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법
|
|
WO2020212832A1
(en)
*
|
2019-04-16 |
2020-10-22 |
Alembic Pharmaceuticals Limited |
Process of preparation of benzimidazole compounds
|
|
US11591395B2
(en)
|
2019-04-19 |
2023-02-28 |
Janssen Biotech, Inc. |
Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
|
|
TWI817018B
(zh)
|
2019-06-28 |
2023-10-01 |
美商艾瑞生藥股份有限公司 |
用於治療ｂｒａｆ相關的疾病和失調症之化合物
|
|
EP3994132A1
(en)
|
2019-07-03 |
2022-05-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
|
JP7763753B2
(ja)
|
2019-09-26 |
2025-11-04 |
ノバルティス アーゲー |
アザキノリン化合物およびその使用
|
|
CN114761006A
(zh)
|
2019-11-08 |
2022-07-15 |
Inserm(法国国家健康医学研究院) |
对激酶抑制剂产生耐药性的癌症的治疗方法
|
|
WO2021116901A1
(en)
*
|
2019-12-09 |
2021-06-17 |
Biocon Limited |
Forms of binimetinib and process for preparation thereof
|
|
BR112022011902A2
(pt)
|
2019-12-20 |
2022-09-06 |
Novartis Ag |
Terapias de combinação
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
EP4122925A4
(en)
*
|
2020-03-17 |
2024-04-17 |
Medshine Discovery Inc. |
Proteolysis regulator and method for using same
|
|
EP4134081A4
(en)
|
2020-04-10 |
2024-05-01 |
Taiho Pharmaceutical Co., Ltd. |
Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor
|
|
TW202426436A
(zh)
|
2020-06-09 |
2024-07-01 |
美商艾瑞生藥股份有限公司 |
用於治療ｂｒａｆ相關的疾病和病症之化合物
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
AR123185A1
(es)
|
2020-08-10 |
2022-11-09 |
Novartis Ag |
Compuestos y composiciones para inhibir ezh2
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
AU2021358394A1
(en)
|
2020-10-05 |
2023-04-13 |
Pierre Fabre Medicament |
Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
CN112679438A
(zh)
*
|
2020-12-31 |
2021-04-20 |
武汉九州钰民医药科技有限公司 |
制备司美替尼的方法
|
|
CN112759552A
(zh)
*
|
2020-12-31 |
2021-05-07 |
武汉九州钰民医药科技有限公司 |
司美替尼的合成方法
|
|
US12141240B2
(en)
|
2021-01-20 |
2024-11-12 |
Rutgers, The State University Of New Jersey |
Method of calibration using master calibration function
|
|
JP2024503893A
(ja)
*
|
2021-01-21 |
2024-01-29 |
エヌフレクション セラピューティクス インコーポレイテッド |
ピロロピリジン－アニリン化合物を調製するための方法
|
|
EP4284838A2
(en)
|
2021-01-28 |
2023-12-06 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
|
JP2024505562A
(ja)
|
2021-02-02 |
2024-02-06 |
レス ラボラトイレス セルビエル |
選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
|
|
US20240310266A1
(en)
|
2021-03-18 |
2024-09-19 |
Novartis Ag |
Biomarkers for cancer and methods of use thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
|
EP4322953A4
(en)
*
|
2021-04-15 |
2025-01-22 |
Ideaya Biosciences, Inc. |
COMBINATION THERAPY WITH A PKC INHIBITOR AND A MEK INHIBITOR
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
US12280055B2
(en)
|
2021-05-27 |
2025-04-22 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
IL307964A
(en)
|
2021-06-09 |
2023-12-01 |
Chugai Pharmaceutical Co Ltd |
Combined treatment for cancer
|
|
CN115490640B
(zh)
*
|
2021-06-17 |
2024-11-26 |
深圳市塔吉瑞生物医药有限公司 |
取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
|
|
CA3226162A1
(en)
|
2021-07-09 |
2023-01-12 |
Plexium, Inc. |
Aryl compounds and pharmaceutical compositions that modulate ikzf2
|
|
EP4426305A1
(en)
|
2021-11-04 |
2024-09-11 |
F. Hoffmann-La Roche AG |
Novel use of quinazolinone compound for the treatment of cancer
|
|
WO2023084489A1
(en)
|
2021-11-15 |
2023-05-19 |
Pfizer Inc. |
Methods of treating coronavirus disease 2019
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
AU2023271885A1
(en)
|
2022-05-20 |
2024-12-12 |
Les Laboratoires Servier |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
CN119562832A
(zh)
|
2022-05-20 |
2025-03-04 |
诺华股份有限公司 |
Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
|
|
WO2023238000A1
(en)
*
|
2022-06-06 |
2023-12-14 |
Glenmark Life Sciences Limited |
Process for preparation of selumetinib and salts thereof
|
|
EP4618994A1
(en)
|
2022-11-18 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
|
|
AU2024234194A1
(en)
|
2023-03-10 |
2025-08-07 |
Novartis Ag |
Panras inhibitor antibody-drug conjugates and methods of use thereof
|
|
AU2023439518A1
(en)
|
2023-04-06 |
2025-08-28 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumors
|
|
TWI905527B
(zh)
|
2023-06-01 |
2025-11-21 |
中化合成生技股份有限公司 |
6-(4-溴-2-氯-苯基胺基)-7-氟-3-甲基-3h-苯并咪唑-5-羧酸(2-乙烯基氧基-乙氧基)-醯胺硫酸鹽晶型ａ、ｂ、ｃ、ｄ、ｅ、ｆ及ｇ及其製造方法
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
PY24103486A
(es)
|
2023-11-22 |
2025-06-06 |
Servier Lab |
Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
|
|
FR3159741A1
(fr)
|
2024-03-04 |
2025-09-05 |
Pierre Fabre Medicament |
Formulation topique comprenant du binimetinib
|
|
WO2025215536A1
(en)
|
2024-04-10 |
2025-10-16 |
Novartis Ag |
Macrocyclic panras inhibitors for the treatment of cancer
|
|
PL249149B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL249150B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL249151B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL248506B1
(pl)
*
|
2025-01-27 |
2025-12-22 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL249148B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL249152B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|